Doximity, Inc.
NYSE:DOCSMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $5.47B
- Beta
- 1.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.06
Volume 2.27M
Average 3.89M
DOCS Sales of Investments
Cash received from selling or redeeming investments.
Doximity, Inc.NYSE: DOCS
Sales of Investments · Q2 FY2027 · quarter ended Sep 2026
Sales of investments dips below year-ago levels
Q2 FY2027 sales of investments of $86.4M fell 31.1% year over year, behind the +4.1% change in trailing-twelve-month sales of investments. Sequentially, it fell 33.6% from the prior quarter. Over 3 fiscal years it compounded at +44.3% a year.
Context
- Sales of investments amounted to 88.7% of revenue in FY2026, down 25.8 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -31.1% toward the trailing-twelve-month pace of +4.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2026
- 571.82M USD
- Year-over-year change
- -12.4%
- 4-year CAGR
- -4.3%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 571.82M | -12.4% |
| FY2025 | 2025-03-31 | 652.78M | +28.0% |
| FY2024 | 2024-03-31 | 509.85M | +167.9% |
| FY2023 | 2023-03-31 | 190.32M | -72.1% |
| FY2022 | 2022-03-31 | 681.72M | — |
Sales of Investments vs competitors
How DOCS compares with its peers on the latest reported figures
- DOCS's LTM Sep 2026 sales of investments of $518.31M is the 2nd largest of the 10 companies compared; the peer median is $7.5M.
- Its year-over-year change of +4.1% is the 4th highest of 7, against a peer median of +94.4%.
- Sales of investments amounts to 78.3% of revenue for DOCS, versus a peer median of 0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.07B | +212.6% | -17.9% | 83.5% | |
| LTM Sep 2026 | $518.31M | +4.1% | +44.3% | 78.3% | |
| LTM Jun 2026 | $413M | +1650.0% | -7.2% | 2.8% | |
| LTM Jun 2026 | $87.6M | -23.8% | — | 1.4% | |
| LTM Jun 2026 | $15.34M | +19678.1% | +56.2% | 0.2% | |
| LTM Jul 2026 | $7.5M | -98.9% | — | 0.3% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Jul 2026 | $0 | — | — | 0.0% | |
| LTM Jul 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DOCS) | $7.5M | +94.4% | -7.2% | 0.2% | |
Competitors are the stored peer set for DOCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 154.78M | 112.82M | 147.58M | 223.19M | 196.05M |
| Depreciation & Amortization | 5.04M | 10.28M | 10.27M | 10.66M | 14.38M |
| Deferred Income Tax | (41.25M) | 13.23M | (8.59M) | (11.59M) | 32.14M |
| Stock-Based Compensation | 31.44M | 47.83M | 51.08M | 72.39M | 121.63M |
| Change in Working Capital | (40.33M) | (21.03M) | (24.52M) | (24.1M) | (45.7M) |
| Accounts Receivables | (31.02M) | (26.24M) | 3.99M | (27.21M) | (16.88M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.66M | (195K) | 8.33M | (663K) | 4.27M |
| Other Working Capital | (17.98M) | 5.4M | (36.85M) | 3.77M | (33.09M) |
| Other Non-Cash Items | 16.89M | 16.47M | 8.29M | 2.72M | 7.96M |
| Operating Cash Flow | 126.58M | 179.6M | 184.1M | 273.27M | 326.46M |
| Capital Expenditures | (5.7M) | (6.18M) | (5.8M) | (6.53M) | (8.96M) |
| Acquisitions (Net) | 0 | (53.5M) | 0 | 0 | (26.53M) |
| Purchases of Investments | (1.32B) | (190.56M) | (472.87M) | (675.56M) | (389.16M) |
| Sales of Investments | 681.72M | 190.32M | 509.85M | 652.78M | 571.82M |
| Other Investing Activities | 595K | 0 | (5.65M) | 0 | 0 |
| Investing Cash Flow | (640.57M) | (59.92M) | 31.19M | (29.3M) | 147.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 553.91M | 0 | 0 | 23.3M | 13.68M |
| Common Stock Repurchased | (2.7M) | (85.32M) | (280.72M) | (120.29M) | (431.65M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.21M | 10.86M | 4.19M | (34.15M) | (46.09M) |
| Financing Cash Flow | 560.42M | (74.46M) | (276.52M) | (131.14M) | (464.06M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 46.42M | 45.22M | (61.24M) | 112.83M | 9.56M |
| Free Cash Flow | 120.88M | 173.42M | 178.3M | 266.74M | 317.5M |
Doximity, Inc.
NYSE:DOCS
Intrinsic Alpha fair value
Locked
Current Price
$30.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.